BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25257150)

  • 1. Radioiodine treatment of Graves' disease - dose/response analysis.
    Cepková J; Horáček J; Vižďa J; Doležal J
    Acta Medica (Hradec Kralove); 2014; 57(2):49-55. PubMed ID: 25257150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
    Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
    Murakami Y; Takamatsu J; Sakane S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3257-60. PubMed ID: 8784079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves' hyperthyroidism.
    Leslie WD; Peterdy AE; Dupont JO
    J Nucl Med; 1998 Apr; 39(4):712-6. PubMed ID: 9544686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized comparison of radioiodine doses in Graves' hyperthyroidism.
    Leslie WD; Ward L; Salamon EA; Ludwig S; Rowe RC; Cowden EA
    J Clin Endocrinol Metab; 2003 Mar; 88(3):978-83. PubMed ID: 12629071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
    Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
    Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
    Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
    Kaplowitz PB; Jiang J; Vaidyanathan P
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM; Shawkat W
    Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses.
    Sztal-Mazer S; Nakatani VY; Bortolini LG; Boguszewski CL; Graf H; de Carvalho GA
    Thyroid; 2012 Oct; 22(10):991-5. PubMed ID: 22953990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal.
    Bogazzi F; Giovannetti C; Fessehatsion R; Tanda ML; Campomori A; Compri E; Rossi G; Ceccarelli C; Vitti P; Pinchera A; Bartalena L; Martino E
    J Clin Endocrinol Metab; 2010 Jan; 95(1):201-8. PubMed ID: 19906789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?
    Bajnok L; Mezosi E; Nagy E; Szabo J; Sztojka I; Varga J; Galuska L; Leovey A
    Thyroid; 1999 Sep; 9(9):865-9. PubMed ID: 10524564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioactive iodine in the treatment of Graves' disease.
    Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H
    Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.